Gerhold Kerstin, Avagyan Angela, Seib Christine, Frei Remo, Steinle Johanna, Ahrens Birgit, Dittrich Anna-Maria, Blumchen Katharina, Lauener Roger, Hamelmann Eckard
Department of Pediatric Pneumology and Immunology, University Hospital Charité, Berlin, Germany.
J Allergy Clin Immunol. 2006 Sep;118(3):666-73. doi: 10.1016/j.jaci.2006.05.022. Epub 2006 Jul 20.
New preventive strategies against the development of allergic diseases focus on potentially immunomodulatory components, such as bacterial LPSs. Optimal time frames for initiating immunomodulation to receive a sufficient effect against allergen sensitization are still unclear.
Using a mouse model, we investigated the influence of prenatal LPS exposure on later allergen-mediated sensitization and airway inflammation in the offspring.
Pregnant BALB/c mice were repeatedly exposed to aerosolized LPS (LPS Escherichia coli; 3x per week, day 7 of gestation time up to delivery). Some of the offspring were further exposed to aerosolized LPS before allergen sensitization with ovalbumin (OVA; administered intraperitoneally day 28 up to day 42) and OVA airway challenges (days 56-58). Positive control animals were placebo exposed to PBS instead of LPS, and negative control animals were first placebo exposed and later placebo sensitized with PBS instead of OVA.
Compared with positive control animals, prenatal LPS exposure suppressed (1) allergen-specific sensitization (IgE production), (2) eosinophilic airway inflammation (reduced numbers of eosinophils in bronchoalveolar lavage fluids), and (3) in vivo airway reactivity in response to methacholine. These effects occurred only when prenatal was combined with further postnatal LPS exposure. Suppression of allergen-mediated inflammatory responses was associated with increased Toll-like receptor and T-bet expression by lung tissues and a shift toward predominantly T(H)1 immune responses in spleen cells cultured with OVA in vitro.
Prenatal initiated and postnatal sustained LPS exposure increased endotoxin susceptibility and prevented later allergen sensitization in offspring through inhibition of T(H)2 immune responses.
Immunomodulation with bacterial compounds during gestation time might be an effective mode for first-step primary prevention against allergic diseases.
针对过敏性疾病发展的新预防策略聚焦于潜在的免疫调节成分,如细菌脂多糖。启动免疫调节以获得针对过敏原致敏的充分效果的最佳时间框架仍不明确。
使用小鼠模型,我们研究了产前暴露于脂多糖对后代随后的过敏原介导的致敏和气道炎症的影响。
怀孕的BALB/c小鼠反复暴露于雾化的脂多糖(大肠杆菌脂多糖;每周3次,从妊娠第7天直至分娩)。一些后代在使用卵清蛋白(OVA;在第28天至第42天腹腔注射)进行过敏原致敏和OVA气道激发(第56 - 58天)之前进一步暴露于雾化的脂多糖。阳性对照动物用PBS代替脂多糖进行安慰剂暴露,阴性对照动物首先进行安慰剂暴露,随后用PBS代替OVA进行安慰剂致敏。
与阳性对照动物相比,产前暴露于脂多糖抑制了(1)过敏原特异性致敏(IgE产生),(2)嗜酸性气道炎症(支气管肺泡灌洗液中嗜酸性粒细胞数量减少),以及(3)对乙酰甲胆碱的体内气道反应性。这些效应仅在产前与产后进一步暴露于脂多糖相结合时才会出现。过敏原介导的炎症反应的抑制与肺组织中Toll样受体和T-bet表达增加以及体外与OVA一起培养的脾细胞中向主要的T(H)1免疫反应转变有关。
产前启动并产后持续的脂多糖暴露增加了内毒素易感性,并通过抑制T(H)2免疫反应预防了后代随后的过敏原致敏。
孕期用细菌化合物进行免疫调节可能是预防过敏性疾病的第一步一级预防的有效模式。